Unter den Marken unserer mehr als 25 Partner sticht TargetMol hervor

SARS-CoV-2 Mpro-IN-41 (Compound 7e) is an orally active inhibitor targeting COX-2 and SARS-CoV-2 Mpro, with respective IC50 values of 9.66 μM and 13.24 μM. It also demonstrates inhibitory activity against COX-1 (IC50: 46.11 μM). This compound significantly suppresses the expression of inflammation-related cytokines such as TNF-α, IL-6, and IL-1β, exhibiting anti-inflammatory properties. By selectively inhibiting COX-2 and SARS-CoV-2 Mpro, SARS-CoV-2 Mpro-IN-41 exerts both anti-inflammatory and antiviral effects, making it a potential candidate for research in inflammation and COVID-19 treatment.

U-46619 serinol amide is a derivative of U-46619, acting as a stable analog of Thromboxane A2 (TXA2). It effectively functions as a TXA2 agonist, capable of inducing platelet shape change and aggregation.

Antibacterialagent 279 (compound A12) is an effective antibacterial agent. It inhibits the SOS response of Pseudomonas aeruginosa.

<p>SMARCA2/4-ligand-6 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs) utilized in the synthesis of SMARCA2/4-ligand-6.</p>

<p>Amobam is a biochemical with the activity of bactericide.</p>

SD-2301 is a PROTAC degrader of STAT3.

PARP1-IN-38 (compound ent-6_P) is a potent PARP1 inhibitor with an IC50 value of 10 μM. It exhibits selective cytotoxic activity in BRCA-mutant cancer cells.

<p>Antidiabetic agent 15 (compound 1B15) acts as a dual inhibitor of AT1R and NEP, reducing oxidative stress and restoring mitochondrial membrane potential.</p>

2,4-D-butyl, a herbicide, is mainly used to control the growth of broadleaf weeds.

<p>PDEδ/NAMPT IN-1 (Compound 17d) is a dual inhibitor targeting phosphodiesterase 6 (PDE6) with a dissociation constant (KD) of 0.410 nM and nicotinamide phosphoribosyltransferase (NAMPT) with an inhibitory concentration (IC50) of 2.21 nM. It disrupts KRAS-related signaling by inhibiting NAMPT's role in the synthesis of nicotinamide adenine dinucleotide (NAD+), consequently inducing apoptosis in pancreatic cancer cells with KRAS mutations. This compound holds potential for research in KRAS-mutant pancreatic cancer.</p>

Trandolaprilat is an inhibitor of non-sulfhydryl angiotensin-converting enzyme.

<p>SARS-CoV-2 Mpro-IN-43 (Compound 1) is an inhibitor of the coronavirus main protease (Mpro) with an IC50 of 72 μM. It exerts its antiviral effects by interacting non-covalently with the key residues at the Mpro active site. This compound exhibits moderate to low cytotoxicity with CC50 values of 13.24, 41.02, and 42.26 µM in HaCaT, HEK293T, and HepG2 cells, respectively. SARS-CoV-2 Mpro-IN-43 is applicable for SARS-CoV-2 research.</p>

<p>KRAS inhibitor-42 (compound 8) is an effective USP7 inhibitor that exhibits high affinity for GDP-bound KRASG12D, with a Ki value of 2.7 μM.</p>

<p>(R,R)-BMS-986397 is a CK1α degrader with a DC50 ranging from 0.1 to 0.5 pM. This compound is applicable in leukemia research.</p>

DDO-6691 is an inhibitor of heat shock protein 90 (HSP90). It exhibits antiproliferative effects against various tumor cells, with the highest sensitivity observed in HCT-116 colon cancer cells (IC50: 1.08 μM). DDO-6691 also demonstrates potent tumor growth inhibition in HCT-116 xenograft mouse models.

XRP44X (XRP 44X) is a potent inhibitor of Ras-Net (Elk-3) pathway.

<p>TRBP-IN-1 (Compound 13j) is an orally active inhibitor of TAR RNA-binding protein 2 (TRBP) with an IC50 of 12.72 μM. It exhibits significant anti-hepatocellular carcinoma (HCC) activity, effectively suppressing proliferation and metastasis of HCC cells [HCCLM3 cells (IC50: 18.96 μM) and SK-Hep-1 cells (IC50: 16.45 μM)]. TRBP-IN-1 modulates miRNA biosynthesis by targeting TRBP, inhibiting the expression of oncogenic miRNAs. It induces apoptosis and pyroptosis in HCC cells by decreasing miRNA levels. TRBP-IN-1 is suitable for research on targeted HCC therapy.</p>

<p>PNT2001 (LY4181530) is an effective prostate-specific membrane antigen (PSMA) ligand with an IC50 of 3.1 nM. It enhances cellular internalization and, when labeled with 177Lu and 225Ac, is applicable for prostate cancer research.</p>

<p>VEGFR-2-IN-68 (13b) is an inhibitor of VEGFR-2 with an IC50 value of 41.51 nM. It can induce apoptosis and cause G2/M cell cycle arrest, as well as exhibit anti-cancer metastasis properties.</p>